Dr. Zhang is the founder and CEO of Insignis Therapeutics Inc., a specialty pharmaceutical company dedicated to developing and commercializing a revolutionary oral epinephrine tablet formulation for emergency treatment of anaphylaxis, a life-threatening allergy. Dr. Zhang has over 25 years of hands on experience in developing new drugs at various pharma and biotech companies, including Bayer, Marinus Pharmaceuticals and Institutes for Pharmaceutical Discovery. Over his pharmaceutical career, Dr. Zhang has played key roles in advancing multiple drug candidates into clinical trials. Dr. Zhang is the co-inventor of ZTALMY® (ganaxolone oral suspension 50 mg/mL) recently approved for CDKL5 deficiency disorder (CDD) in children and young adults. Dr. Zhang also serves as president of 3RServices LLC, a drug development CRO he founded in 2013 to help pharmaceutical/biotech companies translate novel scientific discoveries into important medical cures.

Dr. Zhang holds a PhD in organic chemistry from the University of Illinois, Urbana-Champaign and an Executive MBA from the University of New Haven.